



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bernd Riedl et al.

Serial No.: 10/086,417

Group Art Unit: Unassigned

Filed: March 4, 2002

Examiner: Unassigned

For: ω -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS
AS P38 KINASE INHIBITORS

WD1614
RECEIVED
JAN 9 3 2003
TECH CENTER 1600/2900
- Rom

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

Based on information from foreign associates, it is believed that at least Iranian No. 26555 and Lebanese No. 6124 are patented applications filed in the English language and registered. Copies of the registration certificates and the applications filed are provided herewith.

Iran Patent No. 26555 was filed on January 13, 2000 and Lebanese Patent No. 6124 was filed on January 12, 2000.

Pursuant to 37 CFR §1.97 and §1.98, Applicant identifies the following related copending applications.

Title: Inhibition of RAF Kinase Activity Using Aryl Ureas
Inventor(s): Jill Wood et al.
Filed January 8, 2001, Serial No. 09/755,060
Status: Published

Title: RAF Kinase Inhibitors
Inventor(s): Jill Wood et al.
Filed May 21, 1998, Serial No. PCT/US98/10376

Title: Inhibition of P38 Kinase Activity by Aryl Ureas
Inventor(s): Gerald Ranges et al.
Filed May 23, 1997, Serial No. 08/863,022
Status: Published

Title: Inhibition of p38 Kinase Activity by Aryl Ureas
Inventor(s): Gerald Ranges et al.
Filed September 7, 2001, Serial No. 09/947,761

Title: Inhibition of p38 Kinase by Aryl Ureas
Inventor(s): Gerald Rogers et al.
Filed May 21, 1998, Serial No. PCT/US98/10375

Title: Inhibition of RAF Kinase Using Symmetrical and
Unsymmetrical
Substituted Diphenyl Ureas
Inventor(s): Scott Miller et al.
Filed December 22, 1998, Serial No. 09/776,936

Title: Inhibition of RAF Kinase Using Symmetrical and
Unsymmetrical
Substituted Diphenyl Ureas
Inventor(s): William Scott et al.
Filed December 22, 1998, PCT/US98/26081

Title: Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas
Inventor(s): Jacques Dumas et al.
Filed: August 18, 2000, Serial No. 09/640,780

Title: Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas
Inventor(s): Jacques Dumas et al.
Filed December 22, 1998, PCT/US98/26078

Title: Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted
Heterocyclic Ureas
Inventor(s): William Scott et al.
Filed December 27, 1998, Serial No. 09/472,232

Title: Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted
Heterocyclic Ureas
Inventor(s): Jacques Dumas et al.
Filed December 22, 1998, PCT/US98/26082

Title: Inhibition of P38 Kinase Activity Using Symmetrical and
Unsymmetrical Diphenyl Ureas
Inventor(s): Scott Miller et al.
Filed February 1, 2002, Serial No. 10/060,396

Title: Inhibition of p38 Kinase Using Symmetrical and Unsymmetrical
Diphenyl Ureas
Inventor(s): Scott Miller et al.
Filed: December 22, 1998, PCT/US98/27265

Title: Inhibition of P38 Kinase Using Substituted Heterocyclic Ureas
Inventor(s): Jacques Dumas et al.
Filed December 10, 1999, Serial No. 09/458,014

Title: Inhibition of p38 Kinase Activity Using Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed December 22, 1998, PCT/US98/26080

Title: Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed December 22, 1998, Serial No. 09/776,935

Title: Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed: December 22, 1998, PCT/US98/26079

Title: Inhibition of RAF Kinase Quinoliny, Isoquinoliny or Pyridyl Ureas

Inventor: Jacques Dumas et al.

Filed April 19, 2002, Serial No. 10/125,369

Title: Inhibition of RAF Kinase Quinoliny, Isoquinoliny or Pyridyl Ureas

Inventor: Jacques Dumas et al.

Filed April 19, 2002, Serial No. PCT/US02/12066

Title: Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As p38 Kinase Inhibitors

Inventor: Jacques Dumas et al.

Filed April 20, 2001, Serial No. 09/838,286

Title: Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As p38 Kinase Inhibitors

Inventor: Jacques Dumas et al.

Filed April 18, 2002, Serial No. PCT/US02/12064

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor: Bernd Riedl et al.

Filed: September 10, 2001, Serial No. 09/948,915

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor: Bernd Riedl et al.

Filed: January 12, 2000, Serial No. PCT/US00/00648

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor: Bernd Riedl et al.

Filed: July 12, 2001, National Phase of (Bayer 15 WO)

(PCT/US00/00648)

Title: Inhibition of Raf Kinase Using Quinoliny, Isoquinoliny and Pyridiny Ureas

Inventor: Jacques Dumas et al.

Filed February 7, 2001, Serial No. 09/777,920

Title: Inhibition of Raf Kinase Using Quinoliny, Isoquinoliny and Pyridiny Ureas

Inventor: Jacques Dumas et al.

Filed: January 7, 2002, Serial No. PCT/US02/03361

Title: Method and/or Process for Preparing w-Carboxyaryl Substituted Diphenyl Ureas as raf Kinase Inhibitors

Filed February 11, 2002, Serial No. 10/071,248

Title: Omega-Carboxy Aryl Substituted Diphenyl Ureas as p38 Kinase Inhibitors

Inventor: Bernd Riedl et al.

Filed March 12, 2002, Serial No.10/086,417

Title: Aryl Ureas With Angiogenesis Inhibiting Activity

Inventor(s): Jaques Dumas et al.

Filed February 11, 2002, Serial No.60/354,950

Title: ω -Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors

Inventor(s): Riedl et al.

Filed November 27, 2001, Serial No. 09/993,647

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor(s): Riedl et al.

Filed February 2, 2001, Serial No. 09/773,675

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor(s): Riedl et al.

Filed February 2, 2001, Serial No. 09/773,659

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor(s): Riedl et al.

Filed February 2, 2001, Serial No. 09/773,604

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitor

Inventor(s): Riedl et al.

Filed February 2, 2001, Serial No. 09/773,658

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor(s): Riedl et al.

Filed February 2, 2001, Serial No. 09/773,672

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor(s): Riedl et al.

Filed January 11, 2002, Serial No. 09/758,266

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors

Inventor: Riedl et al.

Filed: July 19, 2001, Serial No. 09/907,970

Title: Aryl Urea Compounds In Combination with Other Cytostatic or Cytotoxic Agents For Treating Human Cancers

Filed December 3, 2001, S.N. 60/354,935

Title: Aryl Ureas As Kinase Inhibitors

Inventor: Jacques Dumas.

Filed: February, 11, 2002, S.N. 60/354,937,

Title: Aryl Ureas With raf Kinase and Angiogenesis Inhibiting Activity

Inventor: Jacques Dumas

Filed: February, 11, 2002, S.N. 60/354,948

Title: Pyridine, Quinoline and Isoquinoline N-oxides as Kinase Inhibitors

Inventor: Jacques Dumas

Filed: February, 11, 2002, S.N. 60/354,935

FEES

No fee is required for this Information Disclosure Statement because:


This Information Disclosure Statement is being filed before the mailing of a first action on the merits after the filing of a Request for Continued Examination Under §1.114.

DEPOSIT ACCOUNT

The Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-

3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-16P4


Date: December 30, 2002

RJT:jph

K:\Bayer\16p4\IDS 122002.dot

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.





Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER-16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Publication No. US 2002/0065296 A1, Publication Date: May 30, 2002, Dumas et al.	
		Publication No. US 2002/0062763 A1, Publication Date: May 30, 2003, Macholdt et al.	
		Publication No. US 2002/012831 A1, Publication Date: September 21, 2002, Widdowson et al.	
		Publication No. US 2002/0082255 a1, Publication Date: June 27, 2002, Eastwood	
		Caplus 113:106314, Abstract of JP 2022650, Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove leuco cyan dye, Noboru Mizukura et al. January 25, 1990.	
		Caplus 113:142130, Abstract of JP 2023337, Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler, Toshihiko Yagi et al., January 25, 1990.	
		Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides. Biliary metabolites of 3,4,4'-trichlorocarbanilide and 3-trifluoromethyl-4,4'-dichlorocarbanilide in the rat", Chemical Life Science, pp. 157-66, 1977.	
		Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments", National Academy of Science of Ukraine, M. V. Kurik et al., pp. 2038-2041, 1996.	
		Caplus 127:273945, "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound database", School of Pharmacy and Chemistry, J. C. Dearden, pp. 93-104, 1996	
		Caplus 126:166148, "Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells", James D. Winkler et al., J. Pharmacol. Exp. Ther. Pp. 956-966, 1996.	
		Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives", November 15, 1982.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/vb:K:\bayer\25a\PTO-1449 10-25-02.dot

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

8

Application Number

Complete if Known

10/086.417

Filing Date

March 4, 2002

First Named Inventor

Bernd Riedl et al.

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

BAYER-16P4

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office 3	Number ⁴	Kind Code ⁵ (if known)				
		EP	0192263B1			8-27-1986		
		EP	0107214A1			5-2-1984		
		WO	0047577			8-17-2000		
		WO	99/21835			5-6-1999		
		WO	99/24635			5-6-1999		
		WO	00/41698			7-20-2000		
		WO	00/42012			7-20-2000		
		WO	01/36403A1			5-25-2001		
		WO	96/13632			5-9-1996		
		WO	99/20617			4-29-1999		
		WO	96/13632			5-9-1996		
		WO	02/24635A2			3-28-2002		
		IR	26555					
		LB	6124					

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 Of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bern Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER-16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas", Dr. A. Wander, October 15, 1969.	
		Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuron and flucofuron by in vitro immunization", G. A. Bonwick et al., J. Immunol. Methods, pp. 163-173, 1996.	
		Caplus 127:34137f, "Preparation of quinoline an dquinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation", Kazuo Kubo et al., May 15, 1997.	
		Caplus 131:58658, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas", Miller, Scott, July 1, 1999.	
		Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas", Jacques Dumas, July 1, 1999.	
		Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38kinase inhibitor", Jacques Dumas, July 1, 1999.	
		Joseph V. Simone, "Cecil Textbook of Medicine", 20th Edition, Vol. 1, 2-3-1997. pp. 1004-1010.	
		Cesar Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors", Vol. 37, No. 38, pp. 6947-6950, 1996.	
		Jacqueline E. van Muijlwijk-Koezen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A ₃ Receptor", J. Ed. Chem. 2000, 43, pp. 2227-2238, January 3, 2000.	
		Jacques Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors", Bioorganic & Medicinal Chemistry Letters, pp. 2051-2054, May 2, 2000.	
		Robert W. Carling et al., "1-(3-Cyanobenxylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D ₄ Receptor with Excellent Selectivity over Ion Channels", J. Med. Chem., 1999, 42, pp. 2706-2715.	
		Abstract WO 9822103, May 28, 1998, John Philip Hedge et al.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\pg. 3 PTO-1449 10-25-02.dot



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 Of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bern Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER-16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Abstract of DE 3305866A1, August 29, 1984, Dr. Acker Rolf-Dieter et al.	
		Abstract of EP 4931(equivalent 4,240,820), K. Dickore e tal. (1980)	
		Dumas, J.. "CAS Structure," May 6, 1997, pages 1-29	
		Scott, Bill, "Substructure (Patent Families)", August 11, 1997, pages 1-19.	
		Scott, Bill, "Substructure #2", November 25, 1997, pages 1-3.	
		"Beilstein number" Collection, 28 pages (1997)	
		"Beilstein Collection", 4 pages (1997)	
		Scott, Bill, "Substructure Search", December 2, 1997, pages 1-51.	
		Substructure Search, pages 1-30. (1997)	
		Derwent World Patents Index Search, pages 20-26. (1997)	
		Abstract of EP 116,932 (1984)	
		Abstract of EP 676,395 (1995)	
		Abstract of EP 202,538 (1986)	
		Abstract of EP 16,371 (1980)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\pg. 4 PTO-1449 10-25-02.dot



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749.	
	AB	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399.	
	AC AND AD	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228.	
	AE	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229.	
	AF	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015.	
	AG	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.	
	AH	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.	
	AI	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604.	
	AJ	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659.	
	AK	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672.	
	AL	A "Notice of References Cited" from the USPTO for U.S. application 09/773,675.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935.	
	AN	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936.	
	AO	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920.	
	AP	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915.	
	AQ	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226.	
	AR	A "Notice of References Cited" from the EPO fro European application EP 98/963809.	
	AS	Supplemental search report from the EPO for European application EP 98/963810.	
	AT	Supplemental search report from the EPO for European application EP 98/965981.	
	AU	Supplemental search report from the EPO for European application EP 00/903239.	
	BA	International search report for International Application No. PCT/US98/10375.	
	BB	International search report for International Application No. PCT/US98/10376.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	International search report for International Application No. PCT/US98/26078.	
	BD	International search report for International Application No. PCT/US98/26079.	
	BE	International search report for International Application No. PCT/US98/26080.	
	BF	International search report for International Application No. PCT/US98/26081.	
	BG	International search report for International Application No. PCT/US98/26082.	
	BH	International search report for International Application No. PCT/US98/24265.	
	BI	International search report for International Application No. PCT/US00/00648.	
	BJ	International search report for International Application No. PCT/US00/00768.	
	BK	International search report for International Application No. PCT/US02/12064.	
	BL	International search report for International Application No. PCT/US02/12066.	
	BM	International search report for International Application No. PCT/US/26081.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot